Imugene brings drug home

Just days after starting a study in the US of Vaxinia, Sydney-based Imugene is already looking to bring the cancer-killing virus treatment to Australia.

The Office of the Gene Technology Regulator today (Tuesday) received an application from global CRO Medpace to conduct a phase one study of Vaxinia in patients with solid cancers that are locally advanced or have spread throughout the body.

Vaxinia is a genetically modified chimeric orthopoxvirus which has the potential to stimulate the immune system to be more responsive to immunotherapies.